Biotechnology Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada – Scilex Holding (NASDAQ:SCLX) Read more
Stockmarkets Google working to fix Gemini AI as CEO calls some responses “unacceptable” Reuters via biedexmarkets.com Read more